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Kimiko Tomioka1*, Keigo Saeki1, Kenji Obayashi1, Yuu Tanaka2 and Norio Kurumatani1Abstract
Background: Risk for lung cancer in workers exposed to benzidine (BZ) and/or beta-naphthylamine (BNA),
which are well-known bladder carcinogens, has been examined in many epidemiological studies, but individual
epidemiological studies generally lack the power to examine the association between BZ/BNA exposure and lung
cancer. We conduct a systematic review and meta-analysis to determine the risk for lung cancer among workers
exposed to BZ/BNA occupationally.
Methods/design: Studies will be identified by a MEDLINE, EMBASE, CDSR, and CINAHL search and by the reference
lists of articles/relevant reviews. Eligible studies will be cohort and case-control studies that report occupational BZ/
BNA exposure and the outcome of interest (lung cancer death/incidence). The method of meta-analysis will be
used to combine standardized mortality ratios (SMRs) and/or standardized incidence ratios (SIRs) from retrospective
and prospective cohort studies and odds ratios (ORs) from case-control studies. Two reviewers will independently
screen articles, extract data, and assess scientific quality using standardized forms and published quality assessment
tools tailored for each study design. Overall pooled risk estimates and their corresponding 95% confidence intervals
(CIs) will be obtained using random effects model. This systematic review and meta-analysis will be conducted
following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines, and results will be
reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Discussion: This review will identify and synthesize studies of the association between occupational BZ/BNA
exposure and lung cancer. The findings will help to identify whether BZ/BNA could cause lung cancer and might
indicate whether workers with exposure to BZ/BNA have a need for preventive measures against non-urological
cancer besides bladder cancer.
Systematic review registration: PROSPERO CRD42014010250
Keywords: Benzidine, Beta-naphthylamine, Lung cancer, Mortality, Incidence, Occupational exposure, Systematic
review, Meta-analysis, ProtocolBackground
Benzidine (BZ) and beta-naphthylamine (BNA), which be-
long to aromatic amines, are classified by the International
Agency for Research on Cancer (IARC) as definite human
carcinogens (Group 1) on the basis of sufficient evidence
of bladder cancer in animals and human beings [1,2]. In
addition to the carcinogenicity on the bladder, some* Correspondence: tkimiko@naramed-u.ac.jp
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risk for cancer at sites other than the bladder (i.e., lungs
[3-5], esophageal [4], liver, gallbladder, and bile duct
[6], intestines and larynx [7], and lymphohematopoietic
[8]). However, epidemiological evidence for BZ- and/or
BNA-induced cancer in sites other than the bladder is
not as strong as for bladder cancer itself. Reasons for
this include the small number of cases among the popula-
tions studied, which diminishes the power of the statistical
analyses, and inconsistency between studies regarding
tumor sites.l Ltd. This is an Open Access article distributed under the terms of the Creative
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routes (e.g., oral, subcutaneous injection, intraperitoneal
injection, and inhalation) in many animal species (e.g.,
mice, rats, hamsters, rabbits, and dogs), and a number of
animal studies indicate that exposure to these chemicals
can increase the incidence of a variety of tumors [1,2,9].
With regard to lung cancers, some studies have reported
that oral administration of BZ produced a high incidence
of lung tumors in mice [10], BNA significantly increased
the incidence of lung adenomas following its intraperito-
neal injection to mice [11], and BNA caused lung tumor
multiplicity following its administration by gavage to
mice [12]. In regard to cancer-causing mechanisms in
humans, it is thought that aromatic amines undergo
metabolic activation by N-hydroxylation of the exocyclic
amine group to form the proposed arylnitrenium ion,
which is the critical metabolite implicated in toxicity
and DNA damage [13,14]. The arylhydroxylamine me-
tabolite can form a DNA adduct. Because DNA adducts
derived from the genotoxic metabolites are recognized
as representative early biomarkers of cancer risk [15,16],
the identification and measurement of chemical-specific
DNA adducts in the target tissue are the most relevant
findings for risk assessment [16,17]. In the case of 4-
aminobiphenyl, which is a prototypical aromatic amine
and is present in significant quantities in tobacco smoke,
DNA adducts were first detected in human urinary blad-
der tissue biopsy samples and exfoliated urothelial cells
[18,19]. Subsequently, adducts were detected in human
lung tissues obtained by surgery or autopsy [20]. The ex-
perimental evidence of lung cancer for BZ and BNA in
mice [10-12] and the detection of DNA adducts of an
aromatic amine from human lung tissues [20] suggest
that BZ and BNA have the potential to cause lung can-
cer in humans.
For occupational epidemiological studies, several studies
have reported significantly increased risk of lung cancer
[3-5]. A cohort study of 1,287 American BNA production
workers [3] found a statistically significant excess risk of
death due to lung cancer. The lung cancer risk was ele-
vated in those with the longest working experience, but
the authors could not investigate exposure-response
trends because more than 80% of the study members were
short-term (less than 1 year) workers. A cohort study of
4,581 Russian aniline-dye production workers [4] showed
a significantly increased risk for lung cancer incidence
among workers employed in BZ- or BNA-exposed jobs.
But lung cancer risk was also significantly elevated among
workers exposed only to other chemicals and among
maintenance workers. A more recent cohort study of 374
US workers exposed to BNA [5] also observed a statisti-
cally significant excess risk of death due to lung cancer.
But the risk for lung cancer was statistically significant not
only in the highest BNA exposure risk group, but alsoamong subjects hired after 1972, employed less than 1
year, or with the lowest BNA exposure risk. The statistical
power of those individual studies was thus inadequate to
allow a proper interpretation of the effect of BZ and/or
BNA on the risk of lung cancer. Additionally, to our
knowledge, there have been no meta-analyses of lung can-
cer risk in workers exposed to BZ and/or BNA.
To examine whether occupational exposure to BZ
and/or BNA is associated with risk of lung cancer, we
conduct a systematic review and meta-analysis with data
from occupational epidemiological studies regarding the
association of BZ and/or BNA with lung cancer risk.
Methods/design
This systematic review and meta-analysis will be con-
ducted following the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [21] and
will be reported in accordance with the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [22]. This systematic review protocol
was registered with the International Prospective Register
of Systematic Reviews (PROSPERO) database (registration
number: CRD42014010250).
Inclusion and exclusion criteria
PRISMA [22] asks authors to describe eligibility criteria
using the PICOS reporting system (which describes the
participants, interventions, comparisons, outcome(s),
and study design of the systematic review). This review
will include observational studies, so we will not require
using an intervention for inclusion. Therefore, in accord-
ance with the MOOSE guidelines [21], we will describe
eligibility criteria by means of the participants/popula-
tion, exposure(s), comparator(s)/control, outcome(s),
and study design (PECOS).
Participants/population
We will include subjects with unequivocal evidence of
occupational exposure to BZ and/or BNA such as dye-
stuff workers, workers of BZ/BNA manufacturing plant,
and rubber industry workers exposed to BZ/BNA, which
was present as a contaminant in antioxidants used in
manufacturing. Subjects who worked at the same factory
and who were exposed to neither BZ nor BNA will be
excluded.
Exposure
For cohort studies, ascertainment of exposure to BZ
and/or BNA should be based on written records of ex-
posure measurements or work history. For case-control
studies, BZ/BNA exposure should be ascertained by se-
cure record (i.e., surgical records), structured interview
where blind to case/control status, interview not blinded
to case/control status, or written self-report.
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For cohort studies, use of a comparator is not a require-
ment for inclusion. For case-control studies, control group
will include subjects who have no history of lung cancer.
Outcome
Our outcome will be lung cancer death and/or lung can-
cer incidence based on clinically confirmed diagnosis
(i.e., death certificates, cancer registry or other national
recording system, or hospital or doctors’ records). Effect
measure will include the standardized mortality ratio
(SMR), standardized incidence ratio (SIR), and odds ra-
tio (OR) for the association between BZ/BNA exposure
and lung cancer risk. The SMR and SIR will be based on
an external comparison group (i.e., national or regional
population), and the OR based on a population- or
hospital-based control group.
Study design
Eligible studies will be comparative observational studies
that report occupational BZ/BNA exposure and the out-
come of interest (lung cancer death and/or lung cancer
incidence). Retrospective cohort studies (also known as
historical cohort studies), prospective cohort studies,
and case-control studies will be included in this review.
Search strategy
The search strategies will be carried out by the research
team and an expert librarian. No language restriction
will be enforced conditional to the provision of an Eng-
lish abstract. A date restriction will not be imposed. We
will search the following electronic databases, from in-
ception, using the same search strategy with alterations
as appropriate for each database: MEDLINE, Excerpta
Medica DataBase (EMBASE), Cochrane Database of Sys-
tematic Reviews (CDSR), and Cumulative Index to Nurs-
ing and Allied Health Literature (CINAHL). Search
terms will include controlled vocabulary and text-words,
and details of the search strategy for MEDLINE are pro-
vided in an additional file (see Additional file 1). Add-
itional studies will be identified from the reference list of
articles and relevant reviews. We will attempt to identify
unpublished studies by contacting authors of included
studies.
Study selection
Study selection will be done in two stages. First, all titles
and abstracts will be independently screened by two re-
viewers against the inclusion/exclusion criteria to iden-
tify potentially relevant studies. Studies that do not meet
specific inclusion/exclusion criteria will be rejected at
this stage, and the reason for rejection will be recorded.
Second, the full text articles of all remaining studies will
be obtained and independently assessed for inclusion bytwo reviewers. Disagreements between the two reviewers
will be resolved by discussion, with the involvement of a
third reviewer where agreement cannot be reached. Mul-
tiple reports of the same study will be counted only
once; the record containing the greatest amount of in-
formation (for example, largest sample size or longest
follow-up period) will be retained. A flow chart showing
details of studies included and excluded at each stage of
the study selection process will be produced following
the PRISMA template.
Data extraction
Data from all included studies will be extracted inde-
pendently by two reviewers into a standardized data col-
lection form (see Additional file 2) which will be piloted
on a sample of five studies and then modified if neces-
sary before full data extraction begins. Discrepancies will
be resolved by discussion, with the involvement of a
third reviewer where necessary. For cohort studies, we
will extract the number of observed deaths or cases, the
number of expected deaths or cases, the effect measure
(i.e., SMR or SIR) and the 95% confidence interval (CI)
for lung cancer (essential), all cancers (if available), and
bladder cancer (if available). We want to collect data on
all cancers and bladder cancer as potential sources of
heterogeneity between the included studies. For the
studies for which the 95% CI is not reported, we will cal-
culate them by the exact probabilities of the Poisson dis-
tribution using the observed deaths/cases and expected
deaths/cases reported in the articles [23]. If a study uses
both national and regional populations to compute the
expected deaths/cases, results based on the regional sta-
tistics will be used because a regional population of
study subjects is preferable to the national population
for controlling geographic differences in disease inci-
dence [24]. For case-control studies, we will extract the
number of the case group and control group, the OR,
and the 95% CI for lung cancer from each included
study. For all included studies, data on the following
study characteristics will be also extracted where avail-
able: year of publication, proportion of male, mean age,
duration of follow-up, duration of exposure, country and
geographic area, industry type, occupational exposure to
chemicals including BZ and BNA, information of
cigarette smoking, study sponsorship, and information
relating to quality assessment. In addition, data on na-
tional incidence rates for lung cancer will be obtained
from GLOBOCAN 2012 estimates [25] and data on na-
tional prevalence of cigarette smoking from WHO Re-
port on the Global Tobacco Epidemic 2013.
Quality assessment
Quality will be assessed by two reviewers and discrepan-
cies resolved by discussion.
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Ottawa scale (NOS) [26]. This assessment scale consists
of eight items that are categorized into three major com-
ponents: selection, comparability, and exposure. For co-
hort studies, a modified version of the NOS [27] will be
used. This modified NOS was developed for assessing
the quality of occupational cohort studies and includes
five quality components: representativeness of the ex-
posed cohorts, exposure assessment/reporting, compar-
ability of exposed and non-exposed cohort, assessment
of outcome, and adequacy of follow-up.
Data synthesis
We will perform meta-analysis to obtain the weighted
average (pooled) of the SMR or SIR for cohort studies
and the OR for case-control studies by using the Com-
prehensive Meta-Analysis (version 2.0) software. Overall
pooled estimates of the SMR, SIR, and OR, denoted
“meta-SMR”, “meta-SIR”, and “meta-OR”, respectively,
together with associated 95% CIs, will be calculated
based on random effects model [28]. Heterogeneity
among included studies will be investigated using the I2
statistic (where thresholds of <25% will be taken to sug-
gest low heterogeneity, <50% to suggest moderate het-
erogeneity, and >75% to suggest high heterogeneity [29])
and Cochran’s Q test (where the significance level for chi
squared will be set at P = 0.1). Publication bias will be in-
vestigated by visual inspection of Begg’s funnel plots and
formally tested using Egger’s regression asymmetry
method [30].
We will use subgroup analyses to attempt to explain
any observed between-study heterogeneity. The covari-
ates considered will be geographic region, cohort/sample
size, follow-up period, year of starting the production of
BZ/BNA, type of exposure to BZ/BNA, type of industry,
occupational exposure to lung carcinogen, SMR/SIR for
all cancers and bladder cancer, national prevalence of
cigarette smoking, and national incidence rate for lung
cancer.
For sensitivity analyses, we will analyze key outcomes
separately by categories of the assessed study quality var-
iables to ascertain whether there are any relations with
quality and outcome. Additionally, we will assess the in-
fluence of individual studies on the overall meta-SMR
(meta-SIR or meta-OR) by re-estimating the overall
effect after omitting each study in turn. We will also
conduct cumulative meta-analysis in the order of publi-
cation year to find the starting point of risk estimate be-
coming statistically significant and clarify the variation
tendency [31].
Discussion
This systematic review will identify and synthesize evi-
dence of the association between exposure to BZ/BNAand lung cancer in humans. The findings of this review
will help to identify whether carcinogenic aromatic
amines such as BZ and BNA could cause lung cancer
and provide industrial physicians and policy makers with
information on whether workers with exposure to these
carcinogenic chemicals have a need for health measures
aimed at preventing non-urological cancer, especially
lung cancer.
We are aware that randomized controlled trials (RCTs)
are considered to provide the strongest evidence regard-
ing an intervention [32,33] and that observational stud-
ies are subject to high risk of bias due to potential
outcome confounding [21]. However, it is impossible to
conduct RCTs about how a human carcinogen chemical
causes additional carcinogenicity because exposing sub-
jects to harmful chemical is unethical. Therefore, only
data from observational studies are available for etio-
logical study about well-known human carcinogen.
These limitations will be discussed in length in our re-
view giving special attention to the possible bias and
estimates’ precision of studies conducted in non-
randomized controlled designs. For another major con-
cern in interpreting our findings, we think that smoking
and occupational exposure to chemicals other than BZ
and BNA are important confounders for our study. It is
especially important to confirm whether subjects have
occupational exposure to chemicals known to be car-
cinogenic for the lung. Therefore, we will gather as
much information as possible about smoking and occu-
pational exposure to chemicals other than BZ and BNA
and conduct subgroup analysis by these important
confounders.
With this systematic review, we hope to provide a bet-
ter understanding of the long-term health effects for
workers exposed to carcinogenic chemicals.
Additional files
Additional file 1: Search strategy. Details of the search strategy for
MEDLINE.
Additional file 2: Data collection form. Data from all included studies
will be extracted independently into this standardized data collection
form.
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